Endokrin Bozucu Kimyasal Maddeler ve Kanser Arasındaki İlişkinin Değerlendirilmesi ve Korunma Önerileri

Abstract

Günümüzde başta çocuklar olmak üzere toplumun geneli için farklı endokrin bo- zucu kimyasal maddelere (EDCler) maruziyet ile ortaya çıkabilecek patolojik du- rumlar çok geniş bir yelpazede gerçekleşebilir. Başta üreme sistemi olmak üzere, birçok sistem ve organ EDC maruziyetinden etkilenebilir. Kanser hem gelişmiş hem de gelişmekte olan ülkelerde tüm yaş grup ve sosyoekonomik düzeyleri ilgilendiren önemli bir patolojik durumdur. Özellikle son yirmi yılda kanser insidansı dünya genelinde önemli bir artış göstermiştir. 2015 yılında dünya genelinde yaklaşık 8,8 milyon kişi kanserden ölmüştür ve aynı ölen her 6 kişiden birinin kanserden öldüğü ifade edilmektedir. Özellikle endüstrinin geliştiği ülkel- erde kanser insidansındaki artış, birçok farklı EDC’lere tek tek ve karışım halinde maruziyet ile ilişkilendirilmektedir. Ancak, EDC’lerin insanlarda hangi kanser- leri ne oranda arttırdığına dair literatürde güvenilir veriler bulunmamaktadır. Bu derleme kapsamında, EDC’lerin kanserle olan ilişkisi kapsamlı bir literatür taraması yapılarak incelenmiştir. Literatürdeki birçok çalışmada meme, prostat, testis, pankreas, Non-Hodgkin lenfoma ve diğer hematopoetik kanserler gibi farklı birçok kanser türünün ortaya çıkışında EDC’lerin etkisinin olabileceği belirtilmiştir. Ayrıca, bu derleme kapsamında toplumun EDC’lerin toksik et- kilerinden korunması, bu bileşiklere karşı toplumun farkındalığın arttırılması ve EDC’lere temas sonrası ortaya çıkabilecek kanser dahil birçok patolojik duru- mun önlenmesini sağlamak amacıyla alınması gereken önlemler sunulmuştur.

Keywords

• kanser,endokrin bozucu kimyasal madde,ftalatlar,bisfenol A

Evaluation of the Association between Endocrine Disrupting Chemicals and Cancer and Prevention Suggestions

Abstract

Today, a wide range pathological conditions can be caused by exposure to en- docrine disrupting chemicals (EDCs) in the general population, particularly in children. The reproductive system is the main target for EDCs whereas several systems and organs can be affected from EDC exposure. Cancer is a pathological condition that affects all of the age groups and socioeconomic classes in both developed and developing countries. Particularly in the last twenty years, cancer incidence is rising throughout the globe. In 2015, nearly 8.8 million people died because of cancer and it is indicated that this corresponds to 1 in 6 of all deaths in the same year. The rise of cancer incidence in particularly industrialized countries is associated with exposure the EDC one by one or in mixtures. However, there is no reliable information in literature about EDCs and how much they can increase different cancer outcomes in humans. In this review, the association of EDCs with cancer is investigated by a comp- rehensive literature evaluation. Several studies in literature indicated that EDCs may have an impact on the outcome of different cancer types, including cancers of breast, pros- tate, testis, pancreas as well as Non-Hodgkin Lymphoma and the other type of hematopoietic cancers. In addition, this review also covers and suggests certain precautions for preventing the toxicity of these chemicals, increasing awa- reness of the society against these compounds and preclu- ding several pathological conditions, including cancer after exposure to endocrine disrupting chemicals.

Keywords

• endocrine system,cancer,endocrine disrupting chemicals,phatalates,bisphenol A

References

1. 1. World Health Organization (WHO). Cancer. 2015. Erişim adresi: http://www.who.int/mediacentre/factsheets/fs297/en/. Son erişim tarihi: 27 Kasım 2017.
2. 2. Türkiye İstatistik Kurumu Haber Bülteni. Ölüm Nedeni İstatistikleri, 2016. Erişim adresi: http://www.tuik.gov.tr/PreHaberBultenleri.do?id=24572. Son erişim tarihi: 27 Kasım 2017.
3. 3. World Cancer Research Fund International. Worldwide Data. Erişim adresi: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data. Son erişim tarihi: 27 Kasım 2017.
4. 4. National Cancer Institute. Risk Factors for Cancer. Erişim adresi: https://www.cancer.gov/about-cancer/causes-prevention/risk. Son erişim tarihi: 27 Kasım 2017.
5. 5. Mayo Clinic. Cancer Overview. Erişim adresi: https://www.mayoclinic.org/symptoms-causes/syc-20370588. Son erişim tarihi: 27 Kasım 2017.
6. 6. Ohshima H, Bartsch H: Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation Research. 1994, 305(2):253-64.
7. 7. MedicineNet. Cancer Risk Factors. Erişim adresi: https://www.medicinenet.com/cancer_causes/article.htm. Son erişim tarihi: 27 Kasım 2017.
8. 8. Environmental Protection Agency (EPA). What is Endocrine Disruption? Erişim adresi: https://www.epa.gov/endocrine-disruption/what-endocrine-disruption. Son erişim tarihi: 27 Kasım 2017.

9. 9. World Health Organisation (WHO). Children's Environmental Health. Endocrine Disrupting Chemicals (EDCs). Erişim adresi: http://www.who.int/ceh/risks/cehemerging2/en/. Son erişim tarihi: 27 Kasım 2017.
10. 10. National Institute of Environmental Health Sciences. Endocrine Disruptors. Erişim adresi: https://www.niehs.nih.gov/health/topics/agents/endocrine/index.cfm. Son erişim tarihi: 27 Kasım 2017.
11. 11. Green R, Hauser R, Calafat AM, Weuve J, Schettler T, Ringer S, Huttner K, Hu H: Use of di(2-ethylhexyl) phthalate-containing medical products and urinary levels of mono(2-ethylhexyl) phthalate in neonatal intensive care unit infants. Environmetal Health Perspectives 2005, 113(9):1222-1225.
12. 12. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC: Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocrine Reviews 2009, 30(4):293-342.
13. 13. World Cancer Research Fund International. Breast Cancer. Erişim adresi: http://www.wcrf. org/int/cancer -facts-figures/data-specific-cancers/breast-cancer-statistics. Son erişim tarihi: 27 Kasım 2017.
14. 14. Lacey JV Jr, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, Hoover RN, Prorok PC, Berg CD, Hartge P; Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team: Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BioMed Central (BMC) Cancer 2009, 9:84.
15. 15. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005, 366:1784–1793.
16. 16. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT: Executive Summary to EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocrine Review 2015, 36(6):593-602.
17. 17. García MA, Peña D, Alvarez L, Cocca C, Pontillo C, Bergoc R, de Pisarev DK, Randi A: Hexachlorobenzene induces cell proliferation and IGF-I signaling pathway in an estrogen receptor alpha-dependent manner in MCF-7 breast cancer cell line. Toxicology Letters 2010, 192(2):195– 205.
18. 18. Calaf GM, Roy D: Cancer genes induced by malathion and parathion in the presence of estrogen in breast cells. International Journal of Molecular Medicine 2008, 21(2):261–268.
19. 19. Liu S, Li S, Du Y: Polychlorinated biphenyls (PCBs) enhance metastatic properties of breast cancer cells by activating rho-associated kinase (ROCK). Plos One 2010, 5(6):e11272.
20. 20. Ptak A, Ludewig G, Rak A, Nadolna W, Bochenek M, Gregoraszczuk EL: Induction of cytochrome P450 1A1 in MCF-7 human breast cancer cells by 4-chlorobiphenyl (PCB3) and the effects of its hydroxylated metabolites on cellular apoptosis. Environment International 2010, 36(8):935–941.
21. 21. Weng YI, Hsu PY, Liyanarachchi S, Liu J, Deatherage DE, Huang YW, Zuo T, Rodriguez B, Lin CH, Cheng AL, Huang TH: Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicology and Applied Pharmacology 2010, 248(2):111–121.
22. 22. LaPensee EW, Tuttle TR, Fox SR, Ben-Jonathan N: Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-α-positive and -negative breast cancer cells. Environmental Health Perspectives 2009, 117(2):175–180.
23. 23. Siewit CL, Gengler B, Vegas E, Puckett R, Louie MC: Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ERα and c-Jun. Molecular Endocrinology 2010, 24(5):981–992.
24. 24. Yu X, Filardo EJ, Shaikh ZA: The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells. Toxicology and Applied Pharmacology 2010, 245(1):83–90.
25. 25. Benbrahim-Tallaa L, Tokar EJ, Diwan BA, Dill AL, Coppin JF, Waalkes MP: Cadmium malignantly transforms normal human breast epithelial cells into a basallike phenotype. Environmental Health Perspectives 2009, 117(12):1847–1852.
26. 26. Fernandez SV, Russo J: Estrogen and Xenoestrogens in breast cancer. Toxicologic Pathology 2010, 38(1):110– 122.
27. 27. Valeron PF, Pestano JJ, Luzardo OP, Zumbado ML, Almeida M, Boada LD: Differential effects exerted on human mammary epithelial cells by environmentally relevant organochlorine pesticides either individually or in combination. Chemico-Biological Interactions 2009, 180(3):485–491.
28. 28. Charles AK, Darbre PD: Oestrogenic activity of benzyl salicylate, benzyl benzoate and butylphenylmethylpropional (Lilial) in MCF7 human breast cancer cells in vitro. Journal of Applied Toxicology 2009, 29(5):422-434.
29. 29. Veselik DJ, Divekar S, Dakshanamurthy S, Storchan GB, Turner JM, Graham KL, Huang L, Stoica A, Martin MB: Activation of estrogen receptor-alpha by the anion nitrite. Cancer Research 2008, 68(10):3950-3958.
30. 30. Anway MD, Leathers C, Skinner MK: Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. Endocrinology 2006,147(12):5515–5523.
31. 31. Jenkins S, Rowell C, Wang J, Lamartiniere CA: Prenatal TCDD exposure predisposes for mammary cancer in rats. Reproductive Toxicology 2007;23(3):391–396.
32. 32. López-Carrillo L, Hernández-Ramírez RU, Calafat AM, Torres-Sánchez L, Galván-Portillo M, Needham LL, Ruiz-Ramos R, Cebrián ME: Exposure to phthalates and breast cancer risk in northern Mexico. Environmental Health Perspectives 2010, 118(4):539-544.
33. 33. Cohn BA, Wolff MS, Cirillo PM, Scholtz RI: DDT and breast cancer in young women: new data on the significance of age at exposure. Environmental Health Perspectives 2007, 115(10):1406–1414.
34. 34. Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New England Journal of Medicine 1971, 284(15):878–881.
35. 35. Herbst AL, Ulfelder H, Poskanzer DC, Longo LD: Adenocarcinoma of the vagina. American Journal Obstetrics and Gynecology 1999, 181(6):1574–1575.
36. 36. Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN: Cancer risk in women prenatally exposed to diethylstilbestrol. İnternational Journal of Cancer 2007, 121(2):356–360.
37. 37. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL: Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environmental Health Perspectives 2005, 113(4):391–395.
38. 38. Calafat AM, Weuve J, Ye X, Jia LT, Hu H, Ringer S, Huttner K, Hauser R: Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants. Environmental Health Perspectives 2009;117(4):639–644.
39. 39. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL: Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environmental Health Perspectives 2008, 116(1):39–44.
40. 40. Carwile JL, Luu HT, Bassett LS, Driscoll DA, Yuan C, Chang JY, Ye X, Calafat AM, Michels KB: Polycarbonate bottle use and urinary bisphenol A concentrations. Environmental Health Perspectives 2009, 117(9):1368–1372.
41. 41. Wolff MS, Teitelbaum SL, Windham G, Pinney SM, Britton JA, Chelimo C, Godbold J, Biro F, Kushi LH, Pfeiffer CM, Calafat AM: Pilot study of urinary biomarkers of phytoestrogens, phthalates, and phenols in girls. Environmental Health Perspectives 2007, 115(1), 116–121.
42. 42. Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A, Sonnenschein C, Watson CS, Zoeller RT, Belcher SM: In vitro molecular mechanisms of bisphenol A action. Reproductive Toxicology 2007, 24(2):178–198.
43. 43. Durando M, Kass L, Piva J, Sonnenschein C, Soto AM, Luque EH, Muñoz-de-Toro M: Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environmental Health Perspectives 2007, 115(1), 80–86.
44. 44. Muñoz-de-Toro M, Markey CM, Wadia PR, Luque EH, Rubin BS, Sonnenschein C, Soto AM: Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. Endocrinology 2005, 146(9):4138–4147.
45. 45. Murray TJ, Maffini MV, Ucci AA, Sonnenschein C, Soto AM: Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure. Reproductive Toxicology 2007, 23(3):383–390.
46. 46. Vandenberg LN, Maffini MV, Schaeberle CM, Ucci AA, Sonnenschein C, Rubin BS, Soto AM: Perinatal exposure to the xenoestrogen bisphenol-A induces mammary intraductal hyperplasias in adult CD-1 mice. Reproductive Toxicology 2008, 26(3–4):210–219.
47. 47. Wadia PR, Vandenberg LN, Schaeberle CM, Rubin BS, Sonnenschein C, Soto AM: Perinatal bisphenol A exposure increases estrogen sensitivity of the mammary gland in diverse mouse strains. Environmental Health Perspectives 2007, 115(4):592–598.
48. 48. World Health Organization (WHO), Globocan 2012: Estimated Cancer İncidence, Mortality and Prevalence Worldwide in 2012 [Erişim Tarihi 30 Kasım 2017]. Erişim adresi: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
49. 49. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics. CA: A Cancer Journal for Clinicians 2006;56:106–130.
50. 50. Prins GS, Korach KS: The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73.233–244.
51. 51. Bjartell A: Genetic markers and the risk of developing prostate cancer. European Urology. 2011, 60(1):29–31.
52. 52. Erkekoğlu P, Rachidi W, Yüzügüllü OG, Giray B, Oztürk M, Favier A, Hıncal F: Induction of ROS, p53, p21 in DEHP- and MEHP-exposed LNCaP cells-protection by selenium compounds. Food and Chemical Toxicology 2011, 49(7):1565-1571.
53. 53. Erkekoglu P, Rachidi W, Yuzugullu OG, Giray B, Favier A, Ozturk M, Hincal F: Evaluation of cytotoxicity and oxidative DNA damaging effects of di(2-ethylhexyl)-phthalate (DEHP) and mono(2-ethylhexyl)-phthalate (MEHP) on MA-10 Leydig cells and protection by selenium. Toxicology and Appllied Pharmacology 2010, 248(1):52-62.
54. 54. Erkekoğlu P, Rachidi W, De Rosa V, Giray B, Favier A, Hincal F: Protective effect of selenium supplementation on the genotoxicity of di(2-ethylhexyl)phthalate and mono(2-ethylhexyl)phthalate treatment in LNCaP cells. Free Radical Biology and Medicine 2010, 49(4):559-66.
55. 55. Prins GS: Endocrine disruptors and prostate cancer risk. Endocrine-Related Cancer 2008, 15(3):649–656.
56. 56. Bidgoli SA, Jabari N, Zavarhei MD: Prostate-specific antigen levels in relation to background factors: are there links to endocrine disrupting chemicals and AhR expression?.Asian Pacific Journal of Cancer Prevention 2014, 15(15):6121-6125.
57. 57. De Coster S ve Van Larebeke N: Endocrine-Disrupting Chemicals: Associated Disorders and Mechanisms of Action. Journal of Environmental and Public Health 2012;2012:52.
58. 58. Parent ME, Désy M, Siemiatycki J. Does exposure to agricultural chemicals increase the risk of prostate cancer among farmers? Mcgill Journal of Medicine 2009, 12(1):70-7.
59. 59. Lutke Holzik MF, Rapley EA, Hoekstra HJ, Sleijfer DT, Nolte IM, Sijmons RH: Genetic predisposition to testicular germ-cell tumours. Lancet Oncology 2004, 5(6):363-371.
60. 60. Jørgensen N, Vierula M, Jacobsen R, Pukkala E, Perheentupa A, Virtanen HE, Skakkebaek NE, Toppari J: Recent adverse trends in semen quality and testis cancer incidence among Finnish men. International Journal of Andrology 2011, 34(4):e37–e48.
61. 61. Aitken RJ, Skakkebaek NE, Roman SD: Male reproductive health and the environment. Medical Journal of Australia 2006, 185(8):414–415.
62. 62. Grady R, Sathyanarayana S: An update on phthalates and male reproductive development and function. Current Urology Reports 2012, 13:307–310.
63. 63. Foster PM: Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. İnternational Journal of Andrology 2006, 29:140–147.
64. 64. Skakkebæk NE, Rajpert-De Meyts E, Main KM: Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Human Reproduction 2001, 16(5):972–978.
65. 65. Kinez J: Endocrine-disrupting chemicals and male reproductive healt. Reproductive BioMedicine Online 2013, 26:440-448.
66. 66. Weidner IS, Møller H, Jensen TK, Skakkebaek NE: Cryptorchidism and hypospadias in sons of gardeners and farmers. Environmental Health Perspectives 1998, 106:793.
67. 67. Ramlau-Hansen CH, Olesen AV, Parrner ET, Sorensen HT, Olsen J: Perinatal markers of estrogen exposure and risk of testicular cancer: follow-up of 1,333,873 Danish males born between 1950 and 2002. Cancer Causes Control 2009, 20(9):1587–1592.
68. 68. Storgaard L, Bonde JP, Olsen J: Male reproductive disorders in humans and prenatal indicators of estrogen exposure. A review of published epidemiological studies. Reproductive Toxicology 2006, 21(1):4–15.
69. 69. Magrath IT: Malignant non-Hodgkin's lymphomas in children. In Pızzo PA, Poplack DG, Principles and Practice of Pediatric Oncology. Fourth edition. Philadelphia J.B. Lippincott. 2002, pp. 661-705.
70. 70. Hardell L, Eriksson M, Lenner P, Lundgren E: Malignant lymphoma and exposure to chemicals, especially organic solvents, clorophenols and phenoxy acids; a case control study. British Journal of Cancer 1981, 43:169-176.
71. 71. Viel JF, Floret N, Deconinck E, Focant JF, De Pauw E, Cahn JY: Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator. Environment International 2011, 37(2):449–453.
72. 72. Merhi M, Raynal H, Cahuzac E, Vinson F, Cravedi JP, Gamet-Payrastre L: Occupational exposure to pesticides and risk of hematopoietic cancers: meta-analysis of case control studies. Cancer Causes and Control 2007, 18(10):1209–1226.
73. 73. Olak J, Colson Y: Gender differences in lung cancer: have we really come a long way, baby? Journal of Thoracic and Cardiovascular Surgery 2004;128:346–351.
74. 74. Nadal A, Alonso-Magdalena P, Soriano S, Quesada I: The pancreatic β-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. Molecular and Cellular Endocrinology 2009, 304:63–68.
75. 75. Alonso-Magdalena P, Laribi O, Ropero AB, Fuentes E, Ripoll C, Soria B, Nadal A: Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environmental Health Perspectives 2005, 113(8):969-977.
76. 76. Sauerland C, Engelking C, Wickham R, Pearlstone DB: Cancers of the pancreas and hepatobilliary system. Seminars in Oncology Nursing 2009, 25(1):76–92.
77. 77. Li XM, Ganmma D, Sato A: The experience of Japan as a clue to the etiology of breast and ovarian cancers: relatioship between death from both malignancies and dietary practices. Medical Hypotheses 2003, 60(2):268–275.
78. 78. Blair A, Dosemeci M, Heineman EF. Cancer and other causes of death among male and female farmers from twenty-three states. American Journal of Industrial Medicine 1993, 23(5):729-742.
79. 79. Porta M, Malats N, Jariod M, Grimalt JO, Rifa J, Carrato A, Guarner L, Salas A, Santiago-Silva M, Corominas JM, Andreu M, Real FX: Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 1999, 354(9196):2125-2129.
80. 80. Dich J, Zahm SH, Hanberg A, Adami HO: Pesticides and cancer. Cancer Causes Control 1997, 8(3):420-443.
81. 81. Ji BT, Silverman DT, Stewart PA, Blair A, Swanson GM, Baris D, Greenberg RS, Hayes RB, Brown LM, Lillemoe KD, Schoenberg JB, Pottern LM, Schwartz AG, Hoover RN: Occupational exposure to pesticides and pancreatic cancer. American Journal of Industrial Medicine 2001, 39(1):92-99.
82. 82. Blair A, Zahm SH: Herbicides and cancer: a review and discussion of methodologic issues. Recent Results Cancer Research 1990;120:132-145.
83. 83. Environmental Protection Agency. Integrated Risk Information System (IRIS) on DDE. (1993). Erişim Adresi: http://www.epa.gov/iris/subst/0328.htm. Son erişim tarihi: 27 Kasım 2017.
84. 84. Kauppinen T, Partanen T, Degerth R, Ojajärvi A: Pancreatic cancer and occupational exposures. Epidemiology 1995, 6(5):498-502.
85. 85. Rudel RA, Gray JM, Engel CL, Rawsthorne TW, Dodson RE, Ackerman JM, Rizzo J, Nudelman JL, Brody JG. Food packaging and bisphenol A and bis(2-ethyhexyl)phthalate exposure: findings from a dietary intervention. Environ Health Perspect. 2011, 119(7):914-20.
86. 86. PEHSU (Pediatric Environmental Health Specialty Units. CONSUMER GUIDE: Phthalates and Bisphenol A. Erişim Adresi: https://www.pehsu.net/_Library/facts/bpapatients_factsheet03-2014.pdf Son erişim tarihi: 27 Kasım 2017.
87. 87. Silent Spring Institute. Tip Sheet: 6 Simple Steps to Avoid BPA and Phthalates in Food. Erişim Adresi: https://silentspring.org/sites/default/files/six_steps.pdf Son erişim tarihi: 27 Kasım 2017.